Evidence map›Paper›PMID 39979897›Full record

ReviewJournal of nanobiotechnology2025

New horizons for the therapeutic application of nanozymes in cancer treatment.

Pravanjan Malla, Yu-Ming Wang, Chia-Hao Su

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Nickel Single-Atom Nanozyme for Multimodal Cancer Therapy.ACS applied materials & interfaces · 2026
    Article
  6. Review
  7. Nanozymes Integrated Biochips Toward Smart Detection System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Recent Advances in Nanozymes Toward Diabetic Foot Ulcers.International journal of nanomedicine · 2026
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pravanjan MallaCenter for General Education, Chang Gung University, Taoyuan, 333, Taiwan.
Yu-Ming WangDepartment of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 833, Taiwan. scorpion@cgmh.org.tw.
Chia-Hao SuCenter for General Education, Chang Gung University, Taoyuan, 333, Taiwan. chiralsu@gmail.com.

Funding

Chang Gung Medical Foundation, Taiwan CMRPD5N0011-3National Science and Technology Council 113-2811-B-182-034
6 · The paper itself

Abstract

The advent of nanozymes has revolutionized approaches to cancer diagnosis and therapy, introducing innovative strategies that address the limitations of conventional treatments. Nanozyme nanostructures with enzyme-mimicking catalytic abilities exhibit exceptional stability, biocompatibility, and customizable functions, positioning them as promising tools for cancer theranostics. By emulating natural enzyme reactions, nanozymes can selectively target and eradicate cancer cells, minimizing harm to adjacent healthy tissues. Nanozymes can also be functionalized with specific targeting ligands, allowing for the precise delivery and regulated release of therapeutic agents, improving treatment effectiveness and reducing adverse effects. However, issues such as biocompatibility, selectivity, and regulatory compliance remain critical challenges for the clinical application of nanozymes. This review provides an overview of nanozymes, highlighting their unique properties, various classifications, catalytic activities, and diverse applications in cancer treatments. The strategic oncological deployment of nanozymes could profoundly impact future advancements in personalized medicine, highlighting recent progress and prospective directions in enzyme-mimetic approaches for cancer treatment. This review summarizes an overview of nanozymes, highlighting their unique properties, various classifications, catalytic activities, and diverse applications in cancer treatments.

Indexed as

Antineoplastic AgentsNanostructuresNeoplasmsAnimalsCatalysisHumansTheranostic NanomedicineAntineoplastic AgentsNanomaterialsReactive-oxygen speciesTherapy

Identifiers

PMID39979897
PMCPMC11844087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.